REGENXBIO INC. (NASDAQ:RGNX) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07.

REGENXBIO Inc. (the Company) held its 2017 annual meeting of
stockholders on May24, 2017. The final voting results are set
forth below. For more information on the following proposals, see
the Companys definitive proxy statement on Schedule14A filed with
the Securities and Exchange Commission on April13, 2017.

(1) The following three persons were elected to serve as ClassII
directors until the Companys 2020 annual meeting of stockholders:

(2) The stockholders ratified the appointment of
PricewaterhouseCoopers LLP as the Companys independent registered
public accounting firm for the year ending December31, 2017:

About REGENXBIO INC. (NASDAQ:RGNX)

REGENXBIO Inc. is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors). Its NAV Technology Platform is applied in the development of approximately 30 product candidates for a range of diseases, including over five internally developed product candidates and approximately 20 partnered product candidates developed by its NAV Technology Licensees. Its therapeutic programs include RGX-501 for Homozygous familial hypercholesterolemia (HoFH); RGX-111 for Mucopolysaccharidosis Type I (MPS I); RGX-121 for Mucopolysaccharidosis Type II (MPS II); RGX-314 for Wet age related macular degeneration (wet AMD), and RGX-321 for X-linked retinitis pigmentosa (XLRP).

REGENXBIO INC. (NASDAQ:RGNX) Recent Trading Information

REGENXBIO INC. (NASDAQ:RGNX) closed its last trading session down -0.20 at 18.65 with 154,778 shares trading hands.